Why Semi-Solid Formulations Fail in Scale-Up and How to Minimize Risk and Maximize Success
Bringing a semi-solid product from development into commercial manufacturing seems straightforward on paper. A formulation works in the lab, stability data look promising, and the next logical step is scaling production. In reality, this is where many programs begin to break down.
Semi-solid products are uniquely sensitive to process variables. Small changes in mixing speed, heating profiles, raw material variability, or equipment geometry can dramatically impact the final product. Sponsors often discover too late that what worked during bench development does not always translate cleanly to larger-scale manufacturing environments.
For companies developing creams, ointments, gels, and lotions, scale-up is not simply a manufacturing exercise. It is a formulation challenge, an engineering challenge, and a process control challenge all at once.
Why Semi-Solid Scale-Up Is So Difficult
Unlike oral solid dosage forms, designing semi-solid formulations is an art of balancing instability—integrating multiple unstable systems into a final stable product while constantly battling internal forces that push the matrix toward failure.
The drug product’s appearance, microtexture, viscosity, spreadability, rheological properties, and stability are all tied directly to how the formulation is processed.
At laboratory scale, formulators often have tight control over every parameter. Small batch sizes allow for careful adjustments and rapid corrections. Once production moves into pilot or commercial-scale equipment, those same controls become far more complex.
A lack of complete understanding of differences in mixing patterns, heat transfer efficiency, cooling rates, vessel geometry, and shear exposure can all alter the final product in meaningful ways. A formulation that appeared stable during development may suddenly exhibit phase separation, viscosity drift, non-homogeneous particle distribution, or poor performance after scale-up.
Process Development Is Just as Important as Formulation Development
A common misconception in semi‑solid development is that formulation alone drives success; in reality, robust process development and deep technical understanding are just as critical.
Manufacturing procedures for semi-solids must be carefully designed and validated alongside the formulation itself. Even slight process deviations can create significant downstream problems. Emulsification rate and timing may affect rheological profile, including droplet size distribution, while cooling profiles may impact crystallization behavior, matrix formation and long-term stability.
These are not minor details. They are directly linked to Critical Quality Attributes of the products like product performance, shelf life, regulatory consistency, and ultimately patient experience.
Sponsors that rely on early formulation houses and delay process optimization until late-stage development often face expensive reformulations, transfer delays, or repeated manufacturing investigations that could have been avoided much earlier in the program.
Raw Material Variability Often Creates Hidden Problems
Semi-solid formulations are also highly sensitive to raw material variability.
Excipients that appear chemically identical on paper may still behave differently during manufacturing because of subtle differences in particle size, rheology, moisture content, or supplier processing methods. At larger manufacturing scales, these variations can become amplified.
This becomes especially problematic when sponsors attempt to accelerate timelines without fully understanding critical material attributes, identifying critical process parameters, and establishing the design space.
Experienced development and manufacturing teams understand that robust supplier qualification and material characterization are essential components of successful scale-up. Without them, scale-up failures can quickly become recurring operational issues.
Why Early Manufacturing Collaboration Matters
Many scale-up problems begin long before manufacturing starts.
Development programs that isolate formulation teams from process development/scale-up teams often create disconnects between laboratory assumptions and commercial production realities. By the time commercial manufacturing teams become involved, critical process decisions may already be difficult to change.
This is why sponsors increasingly seek CDMO partners like CPL that can integrate formulation development, analytical support, process optimization, scaleup, and commercial manufacturing planning early in the program lifecycle.
At CPL, semi-solid development is handled by an experienced technical team keeping commercial scalability in mind from the very beginning. Rather than treating scale-up as a later-stage hurdle, CPL works to align formulation strategy with manufacturing realities early enough to reduce downstream risk and improve long-term consistency.
That collaborative approach becomes especially valuable for pharmaceutical companies navigating aggressive timelines and increasingly sophisticated formulations.
Preventing Scale-Up Failures Before They Happen
Successful scale-up requires more than technical capability alone. It requires planning, early communication, and operational discipline.
The companies that consistently avoid scale-up setbacks tend to prioritize early process development, pilot-scale evaluation, equipment compatibility assessments, and robust analytical testing before commercial manufacturing begins.
The earlier these conversations happen, the easier it becomes to prevent expensive surprises and delays later.
For sponsors developing liquid and semi-solid products, selecting a development and manufacturing partner such as CPL may ultimately determine whether a formulation reaches the market efficiently or becomes trapped in a prolonged cycle of redevelopment and troubleshooting.